Overview

FUTURE 3 Study Extension

Status:
Completed

Trial end date:
2020-05-29

Target enrollment:

Participant gender:

Summary

The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).

Phase:

Phase 3

Details

Lead Sponsor:

Actelion

Treatments:

Bosentan